One-Time gene shot aims to tame rare copper disorder

NCT ID NCT04537377

Ongoing Disease control Sponsor: Vivet Therapeutics SAS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single dose of VTX-801 gene therapy in 4 adults with Wilson's disease, a rare condition where copper builds up in the body. The goal is to see if the treatment is safe and can help control copper levels, possibly allowing patients to stop their usual medications. Researchers will follow participants for up to 5 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Wilson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WILSON'S DISEASE

Contacts and locations

Show contact details

Locations

Aarhus University Hospital

Aarhus, 8200, Denmark
Advent Health

Orlando, Florida, 32803, United States
Royal Surrey County Hospital

Guildford, Surrey, GU2 7XX, United Kingdom
UC Davis Medical Center

Sacramento, California, 95817, United States
University Hospital Essen

Essen, 45147, Germany
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75235, United States
Universitätsklinikum Tübingen (UKT)

Tübingen, 72076, Germany
Wake Forest School of Medicine

Winston-Salem, North Carolina, 27157, United States
Yale University School of Medecine

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.